Lethally severe neurotoxicity continues to haunt Juno’s CAR-T pipeline
With the oncology world looking for an update on the leading CAR-T players at ASH after Juno Therapeutics $JUNO put its lead program for JCAR015 back on clinical hold following 2 new deaths from cerebral edema, the biotech was forced to concede Saturday that investigators had tracked 6 cases of severe, grade 3-5 neurotoxicity out of 24 patients in a separate JCAR014 trial for chronic lymphocytic leukemia. And one of the patients died after developing grade 5 cytokine release syndrome and cerebral edema (brain swelling).
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters